• Oktay Halit Aktepe, Gürkan Güner, Deniz Can Güven, Taha Koray Şahin, Fadime Sinem Ardıç, Deniz Yüce, Şuayib Yalçın, and Mustafa Erman.
• Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
• Turk J Med Sci. 2021 Apr 30; 51 (2): 757-765.

Background/AimThe prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC patients.Materials And MethodsA total of 150 patients receiving TKIs were retrospectively analyzed. Progression-free survival and OS times were analyzed with the Kaplan–Meier method, and the log‐rank test was used for comparison. Univariable and multivariable Cox regression models evaluated the impact of NLR and PLR on OS of the patients. The receiver operating characteristic curve analysis determined that the optimal cut-off values of NL, and PLR in predicting OS were 2 and 204, respectively.ResultsPatient with PLR > 204 had significantly lower median OS time than those with PLR ≤ 204 (14.6 months vs. 31.6 months, P < 0.001). While the univariate analyses showed that both NLR and PLR associated with OS (NLR: P = 0.002; PLR: P < 0.001), PLR, not NLR, was an independent determinant for OS in the multivariate analyses (Hazard Ratio: 2.535, 95% CI: 1.564-4.108, P < 0.001). Additionally, the presence of brain metastases and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic scoring system were identified as independent prognostic factors for OS (brain metastases: P = 0.040; IMDC: P < 0.001).ConclusionThe PLR is a readily and inexpensively obtained marker, which may predict OS in patients with mRCC treated with TKIs.This work is licensed under a Creative Commons Attribution 4.0 International License.

38 keywords...

hide…